Cyprotex works with Pfizer
Aim is to improve predictive toxicology
Pre-clinical ADMET services company Cyprotex’s US subsidiary Apredica has signed an 18-month, two-stage deal with Pfizer, a long-time client. This is described as “a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology”.
This follows on from a recent non-exclusive licensing agreement under which Cyprotex will use Sigma Life Science’s CompoZr zinc finger nuclease technology to ADMET field to create a range of proprietary cell-based assays for drug candidate screening. Cyprotex said that this will enable it to offer detailed, specific, mechanistic assays to investigate the interaction of test compounds with MDR1, BCRP and MRP2 transporters.